Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Products and Global Markets https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html ... The objective of the study is to present ... reproductive technologies and products. Markets are divided according ... some markets are mature, while products in other ...
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, ... a corporate sponsor for MassBio,s 20th Annual Golf Classic, ... MassBioEd Foundation. The event will be held on September ... Plymouth, Massachusetts . The ... Massachusetts through educational programs, workforce development, ...
(Date:9/2/2014)... Ore. -- Scientists, including University of Oregon chemist ... create scaffolds of self-assembling, synthetic proteins called peptoid ... , The accomplishment -- detailed this week in ... the Proceedings of the National Academy of ... alternative design of the two-dimensional peptoid nanosheets that ...
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International Corporation ... its wholly-owned subsidiary Renuell Int,l, Inc. has signed an ... Space Administration ("NASA") at the Johnson Space Center in ... See photos: tapplic.com/houstonphotos/ ... very pleased to announce our latest, exclusive agreement with ...
Breaking Biology Technology:Human Reproductive Technologies: Products and Global Markets 2Human Reproductive Technologies: Products and Global Markets 3Human Reproductive Technologies: Products and Global Markets 4Human Reproductive Technologies: Products and Global Markets 5Human Reproductive Technologies: Products and Global Markets 6Human Reproductive Technologies: Products and Global Markets 7Human Reproductive Technologies: Products and Global Markets 8Human Reproductive Technologies: Products and Global Markets 9Human Reproductive Technologies: Products and Global Markets 10Human Reproductive Technologies: Products and Global Markets 11Human Reproductive Technologies: Products and Global Markets 12Human Reproductive Technologies: Products and Global Markets 13Human Reproductive Technologies: Products and Global Markets 14Human Reproductive Technologies: Products and Global Markets 15Human Reproductive Technologies: Products and Global Markets 16Human Reproductive Technologies: Products and Global Markets 17Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3
... dispute NimbleGen releases microarrays for DNA encyclopedia ... percent Icon Interactive lands animator as client ... managemenet Teklynx releases design software for UCC-compliant ... Benitec in contract dispute , Promega , an international ...
... In his new book The Art of the ... , Guy Kawasaki, a managing director of Garage Technology ... venture capital, most entrepreneurs would be better off spending ... relationships. , ,This is a good message, but ...
... will have a new resource to help them navigate ... related centers on campus. , ,The Office of Corporate ... , which is to include events, publications and both ... to UW=-Madison faculty, staff and students. , ,Were one ...
Cached Biology Technology:Tech Digest (11/10/2004) 2Sarcasm and rainmaking advice coexist in The Art of the Start 2Sarcasm and rainmaking advice coexist in The Art of the Start 3Sarcasm and rainmaking advice coexist in The Art of the Start 4Sarcasm and rainmaking advice coexist in The Art of the Start 5UW plans entrepreneurship program to link campus resources 2
(Date:9/2/2014)... considered the most ideal source of nutrition for ... role in the evolution and civilizations of human ... a large number of bacterial species, including some ... no surprise to scientists and physicians. , Indeed, ... be the result of co-evolutionary and co-adaptive interactions ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
(Date:9/2/2014)... N.C. -- When you accidentally touch a hot oven, ... the basic neural circuits involved in sensing and responding ... the molecular players. , Duke researchers have made a ... involved in pain in worms, and have built a ... 2 in Nature Communications , may help direct ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Risk of diabetes in children and adolescents exposed to antipsychotics 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... Department of Community Health (MDCH) has unveiled the ... includes significant recommendations developed from medical research conducted ... Eunice Kennedy Shriver National Institute for Child Health ... at the Wayne State University School of Medicine. ...
... press release is available in German . ... great happiness among inhabitants. On those days the air is ... difficult and unhealthy. According to the latest calculations of Max ... most of world population in 2050 if no counteractive measures ...
... Butterflies learn faster when a flower is rewarding than when ... when it comes to speed of learning with rewards. These ... Kandori and Takafumi Yamaki from Kinki University in Japan. Their ... Science of Nature , is the first to investigate and ...
Cached Biology News:State of Michigan adopts NIH's PRB progesterone therapy to combat infant mortality 2State of Michigan adopts NIH's PRB progesterone therapy to combat infant mortality 3Worldwide increase of air pollution 2Rewarding work for butterflies 2
Polyclonal Antibody to CLAN...
Request Info...
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biology Products: